We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
OCT Clinical, a leading CRO in Russia and Eastern Europe, has formally incorporated Biostatistics and Clinical Data Management departments of Data MATRIX, an eClinical-technology company focused on solutions that automate the processes of clinical trials. The company announced the news earlier this month, saying that Data MATRIX’s expertise in clinical data management and biostatistics and eClinical solutions will help OCT Clinical to enhance their own CRO services and capabilities being able to offer full-service packages to its clients.
Improving the performance of the target company is the primary goal of the strategy.
"We are excited to welcome the highly qualified team of biostatisticians and clinical data management professionals to our company. We will work together to enhance OCT’s current clinical trial service offerings and to deliver new expertise and solutions to the industry marketplace. Besides, now we can run projects not only on various proprietary validated platforms, but on our own in-house EDC, which enables us to meet clients' timelines and budgets with greater efficiency," says Irina Petrova, Direct of Clinical Operations at OCT Clinical.
Is OCT Clinical CRO looking toward becoming the biggest contract research organization in its region? Particularly, in the light of its recent partnership with a U.S.-based biotech company and their collaborative project — a multinational multicenter clinical study in CNS across six countries of the Eastern European and CIS region.
"We believe that this was much more than a simple combination of businesses. We are focused on becoming much better rather than simply larger. This is a big difference. This initiative seamlessly complements our existing scope of clinical trial services, allowing our operations to further build upon the success we’ve been achieving in clinical development for more than 15 years," said Dmitry Sharov, President of OCT Clinical CRO. "We look forward to continuing to fuel our Sponsors’ and industry partners’ growth with the same personalized business approach our company has become known for."
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
